Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
With the FDA due to approve Madrigal's MASH drug, Ionis is raising its hand to showcase a phase 2 asset that has improved symptoms of the disease.
Annalee Armstrong
Mar 13, 2024 9:54am
BioVie cuts 'most de-risked program,' will seek partner
Mar 11, 2024 11:12am
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Feb 26, 2024 10:49am
NGM to go private as part of $135M buyout by VC firm Column
Feb 26, 2024 10:26am
Gilead pays $4.3B for CymaBay's late-stage liver disease med
Feb 12, 2024 9:01am
Pliant liver disease med passes high-dose test but doesn't wow
Feb 5, 2024 10:40am